Tag Archives: AMPLIFY Phase III trial

AstraZeneca’s Calquence Combination Therapy Approved for Untreated CLL in Europe Following Positive AMPLIFY Phase III Results

(IN BRIEF) AstraZeneca’s Calquence, in combination with venetoclax, with or without obinutuzumab, has been approved by the European Commission for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). The approval follows the positive results from the … Read the full press release